|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/5383 | (2006.01) |
| A61K 31/662 | (2006.01) | ||
| A61P 9/10 | (2006.01) |
| (11) | Number of the document | 2252300 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09711944.0 |
| Date of filing the European patent application | 2009-02-20 | |
| (97) | Date of publication of the European application | 2010-11-24 |
| (45) | Date of publication and mention of the grant of the patent | 2016-10-19 |
| (46) | Date of publication of the claims translation | 2017-02-10 |
| (86) | Number | PCT/US2009/034718 |
| Date | 2009-02-20 |
| (87) | Number | WO 2009/105675 |
| Date | 2009-08-27 |
| (30) | Number | Date | Country code |
| 30903 | 2008-02-22 | US |
| (72) |
MASUDA, Esteban, US
SCHMITZ, Jochen, US
|
| (73) |
Rigel Pharmaceuticals, Inc.,
1180 Veterans Boulevard, South San Francisco, CA 94080,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | 2,4-Pirimidindiaminų panaudojimas aterosklerozės gydymui |
| USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS |
| Payment date | Validity (years) | Amount | |
| 2023-01-31 | 15 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-02-20 |